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Epidermodysplasia verruciformis (EV) is an autosomal recessive skin disorder with
a phenotype conditional on human beta-papillomavirus (beta-HPV) infection. Such
infections are common and asymptomatic in the general population, but in individuals
with EV, they lead to the development of plane wart-like and red or brownish papules or
pityriasis versicolor-like skin lesions, from childhood onwards. Most patients develop
non-melanoma skin cancer (NMSC), mostly on areas of UV-exposed skin, from the
twenties or thirties onwards. At least half of the cases of typical EV are caused
by biallelic loss-of-function mutations of TMC6/EVER1 or TMC8/EVER2. The cellular
and molecular basis of disease in TMC/EVER-deficient patients is unknown, but a
defect of keratinocyte-intrinsic immunity to beta-HPV is suspected. Indeed, these
patients are not susceptible to other infectious diseases and have apparently normal
leukocyte development. In contrast, patients with an atypical form of EV due to inborn
errors of T-cell immunity invariably develop clinical symptoms of EV in the context of
other infectious diseases. The features of the typical and atypical forms of EV thus
suggest that the control of beta-HPV infections requires both EVER1/EVER2-dependent
keratinocyte-intrinsic immunity and T cell-dependent adaptive immunity.
Keywords: epidermodysplasia verruciformis, beta-HPV, TMC/EVER, non-melanoma skin cancer, primary
immunodeficiency
INTRODUCTION
Epidermodysplasia verruciformis (EV) is a rare skin disease characterized by persistent
disseminated flat warts and pityriasis versicolor-like lesions, associated with a high risk of non-
melanoma skin cancer (NMSC). About 501 patients have been reported worldwide (Burger
and Itin, 2014; Imahorn et al., 2017). EV was first described in Lewandowsky and Lutz (1922)
as a congenital skin disease. The observation of parental consanguinity and familial cases led
to the suggestion that EV might be a genetic disease with autosomal recessive inheritance
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(Cockayne, 1933; Rajagopalan et al., 1972). This notion was
not confirmed until 70 years later, when inactivating mutations
of the EVER1/TMC6 and EVER2/TMC8 genes accounting for
about 50% of all known cases of EV were identified (Ramoz
et al., 2002; Orth, 2006, 2008; Imahorn et al., 2017). Auto-
and heteroinoculation experiments performed from 1946 onward
showed that the phenotype of EV was dependent on a viral
infection (Lutz, 1946; Jablonska and Milewski, 1957). Viral
particles were then detected in EV lesions (Ruiter and van
Mullem, 1966; Jablonska et al., 1968), and, subsequently, EV-
specific human papillomaviruses (HPVs) were identified, some of
which, such as HPV-5 in particular, were shown to be associated
with the cancers observed in EV patients (reviewed in Orth
et al., 1980; Orth, 2006). EV thus results from a genetically
determined susceptibility to specific skin-tropic HPVs (Orth,
2006, 2008; Imahorn et al., 2017). These viruses belong to the
beta-genus, and are almost ubiquitous and apparently benign
in the general population. EV patients are not prone to other
viral, bacterial, or fungal infections. NMSC is the only type
of cancer presenting a higher incidence in these patients than
in the general population (Orth, 2006, 2008). The EVER1 and
EVER2 proteins are thought to govern keratinocyte-intrinsic
immunity to beta-HPVs. However, patients with cutaneous
clinical symptoms of beta-HPV infection and other infectious
manifestations caused by profound T-cell defects have been
reported. This clinical picture is referred to as “atypical EV.”
The cumulative findings of almost a century of studies of typical
and atypical EV suggest that both keratinocytes and T cells
are required for the control of beta-HPVs. We review here the
various facets of EV.
CLINICAL MANIFESTATIONS AND
HISTOPATHOLOGY OF EV
EV manifests as multiple polymorphic skin lesions, which
begin to appear during infancy or early childhood and
persist throughout the individual’s life. Flat-topped papular
lesions resembling verrucae planae typically develop on the
extremities. The lesions may also present as red or red-
brownish papules or pityriasis versicolor-like lesions, mostly
on the trunk, neck, and face (Lewandowsky and Lutz, 1922).
In addition, verruca-like papillomatous or seborrheic keratosis-
like lesions may develop. The frequency of verruca vulgaris
is no higher in these patients than in the general population.
In many patients, isomorphic lesions develop preferentially
at sites of traumas (the Koebner phenomenon) (de Oliveira
et al., 2003). Some patients have persistent palmar lesions
similar to palmar pits and dermatoscopically consistent with
plane warts (Imahorn et al., 2017). Over the course of the
patient’s lifetime, the phenotype of a particular skin area may
change, and lesions may progress to NMSC. There is currently
no cure for EV. The development of EV lesions cannot
be prevented, but frequent examinations of skin lesions that
might develop into skin cancers and appropriate treatment of
these lesions are recommended, such as surgical removal and
cryotherapy. Patients with typical EV are otherwise healthy
and are not particularly susceptible to any other unusually
severe infectious diseases. Provided that cancers are treated
appropriately, life expectancy is similar to that in the general
population; multifocal carcinomas might, however, be fatal if
untreated. Histological examinations of lesions typically reveal
hyperkeratosis and parakeratosis, mild acanthosis, and the
presence of koilocytes, keratinocytes with pale-stained cytoplasm
in the upper epidermis associated with high levels of intranuclear
viral replication. On hematoxylin-eosin staining, the cytoplasm
of the affected cells stains pale blue (so-called “blue cells”) and
numerous round basophilic keratohyalin granules are visible.
This histological finding is pathognomonic for infections with
HPV (Orth, 2006). Possible immune infiltration has not been
comprehensively characterized in EV lesions. A number of
atypical EV cases have been reported, which will be reviewed
below.
CLINICAL MANIFESTATIONS OF
ATYPICAL EV
Patients with atypical EV have a broader clinical phenotype than
those with typical EV. The phenotype of EV, as described above,
is undistinguishable between patients with typical and atypical
forms. Indeed, the skin lesions develop early in life and are caused
by the same beta-HPV subtypes that are found in patients with
typical EV (see Table 1). The other clinical phenotypes, mostly
infectious and auto-immune, differ between patients (Crequer
et al., 2012a,b; Sanal et al., 2012; Stray-Pedersen et al., 2014;
Stepensky et al., 2015; Li et al., 2016; Platt et al., 2017; Tahiat
et al., 2017). The clinical features of patients with atypical EV are
reviewed in Table 1. Some patients have growth retardation or
mild developmental delay. Others present auto-immune features,
which may be clinically overt and affect various tissues and
organs, or covert, with detectable auto-antibodies but no clinical
signs. Bacterial infections, including skin abscesses, pneumonia,
and ear infections, are frequent. Infections with cutaneous
herpes viruses, molluscum, mucocutaneous candidiasis, and non-
beta-HPV infections have also been documented. Moreover,
some patients display recurrent respiratory and gastrointestinal
infections. Cancers, such as Burkitt lymphoma and EBV-
lymphoma, have been reported in some patients. Finally, a few
patients have been reported to display clinical manifestations
of beta- and alpha-HPV co-infections in different lesions
(Azzimonti et al., 2005; Borgogna et al., 2014; Landini et al.,
2014). These patients display cutaneous alpha- and beta-HPV-
(Borgogna et al., 2014) or genital (Landini et al., 2014) alpha-
HPV-driven infections, but no broad susceptibility to infections.
These cases suggest that covert immunological abnormalities
might favor the development of beta- and alpha-HPV-induced
cutaneous and mucosal lesions in other individuals. Based on
these clinical observations, the molecular and cellular basis of
typical and atypical EV phenotype appear to be different. The
typical EV phenotype is, in itself, suggestive of a keratinocyte-
intrinsic defect, whereas the atypical EV phenotype, with
its myriad of infections and auto-immune features, is more
consistent with an adaptive T-cell defect.
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SKIN CANCER
Patients with EV have a higher than normal risk of developing
actinic keratosis and NMSC, particularly cutaneous squamous
cell carcinoma (cSCC), cSCC in situ (Bowen’s disease) and, to a
lesser extent basal cell carcinoma (BCC) (Lewandowsky and Lutz,
1922; Rajagopalan et al., 1972; Orth et al., 1979; Mitsuishi et al.,
2008). About two third of EV patients develop NMSC, with an
onset during their twenties or thirties (Lewandowsky and Lutz,
1922; Rajagopalan et al., 1972; Orth et al., 1978; Majewski and
Jablonska, 1997; de Oliveira et al., 2003). NMSC typically occurs
in lesions exposed to the sun, about 20 years after the appearance
of the first lesions, suggesting that UV irradiation and HPV are
cocarcinogens for the development of this cancer. EV patients
should, therefore, pay particular attention to protecting their skin
against exposure to the sun. The role of HPVs in carcinogenesis
is well established. The first evidence for the oncogenic behavior
of HPVs was actually documented in a study of EV (Orth et al.,
1980). EV has long served as a human model for studies of
viral cutaneous oncogenesis (Jablonska et al., 1972; Casanova
and Abel, 2004). This oncogenic behavior of beta-HPVs led
to speculations that these viruses might also contribute to the
development of cSCC in the general population. However, in
cases of cSCC in the general population, less than one viral
genome per cell is generally detected; by contrast, viral load
is very high in cSCC of EV patients, indicating that different
mechanisms of cancer initiation and maintenance are probably at
work (Howley and Pfister, 2015). In particular, oncogenic HPV-
5 and HPV-8 have been found in EV-associated NMSC, leading
to their classification, by the WHO, as possible carcinogens
in EV patients (Bouvard et al., 2009). The detection of high
loads of HPV-5 E6 and E7 transcripts suggested a role in
the cancer induction or maintenance, although the underlying
mechanism remains unclear (Orth, 1987). Radiotherapy for cSCC
treatment can be effective in the general population, but is
counterproductive in EV patients, as the development of more
aggressive tumors after treatment has been reported (Rajabi
et al., 2014; de Oliveira et al., 2015). Patients should undergo
frequent physical examinations, to facilitate the identification of
precancerous and cancer lesions as early as possible. However,
it has been shown that infection with oncogenic HPVs known
to be associated with a high risk of skin cancer is not sufficient,
in itself, to cause cancer. Environmental and genetic factors thus
contribute to the inter-individual variability of outcome for HPV
infection.
VIRAL ETIOLOGY
More than half a century ago, EV was recognized as a virus-
induced disease, based on several experimental observations.
Inoculation experiments showed EV to be transmissible (Lutz,
1946; Jablonska and Milewski, 1957; Jablonska et al., 1966). The
first viral particles were then detected in lesions by electron
microscopy (Ruiter and van Mullem, 1966; Jablonska et al., 1968)
and, several years later, the first EV-specific HPV types, all from
genus beta-HPV, were isolated from EV lesions (Orth et al., 1978;
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Orth, 1986). EV patients not only have high HPV loads in their
lesions, they also have a high serum antibody reactivity to beta-
HPVs (Michael et al., 2010). At least 25 different beta-HPV
genotypes have been found in patients with EV, and patients are
usually infected with multiple EV-HPV types, HPV-5 being the
most prevalent genotype (Orth, 2006). HPV-5 is also the most
common genotype in cases of malignant conversion (Orth, 1986;
Imahorn et al., 2017). Beta-HPVs are also frequently found in
the skin of healthy individuals of the general population, but
mostly at low copy numbers, and they do not cause clinical
disease. This suggests that beta-HPVs are commensals of the
skin (Antonsson et al., 2003a,b). However, it remains a matter
of debate whether these beta-HPVs are really non-pathogenic
in individuals without EV, as some studies have associated
EV-HPV seropositivity and viral DNA load in the eyebrow
with the risk of cSCC in the general population (Neale et al.,
2013; Iannacone et al., 2014). The mechanisms of persistent,
asymptomatic EV-HPV infection remain largely unknown. It
has been suggested that beta-HPVs lack an essential growth-
promoting function, limiting their pathogenicity. Indeed, unlike
the alpha- and gamma-HPVs responsible for cutaneous warts,
cervical cancers, and laryngeal papillomatosis, beta-HPVs do not
possess the E5 or E8 (also reported as E101) open-reading frames
typically found in pathogenic non-beta HPVs and shown to be a
growth-promoting factor for keratinocytes in vivo (Danos et al.,
1983; Giri et al., 1985; Hu et al., 2002; Nonnenmacher et al.,
2006; Orth, 2006, 2008). Beta-HPVs can overcome this lack of a
growth-promoting function and attain full pathogenicity, only in
genetically predisposed individuals, implying that these patients
have a specific cutaneous immune defect (reviewed by Orth, 2006,
2008).
HUMAN GENETICS OF TYPICAL EV
Typical EV is a Mendelian condition that is transmitted as an
autosomal recessive trait and shows complete penetrance in the
first decade of life, across different ethnic groups (Orth, 2006). An
autosomal recessive mode of inheritance was initially proposed in
Cockayne (1933), confirmed in 1974 (Rajagopalan et al., 1972)
and subsequently supported by a study of 147 EV cases, in
which 11% of patients were the offspring of consanguineous
marriages, and 10% came from multiplex families in which 25%
of the siblings were affected, with an equal sex ratio (Lutzner,
1978). Shortly after the mapping of two susceptibility loci for
EV to chromosomes 17q25 (EV1) and 2p21-p24 (EV2) (Ramoz
et al., 1999, 2000), bi-allelic loss-of-function mutations of two
adjacent genes termed TMC6 and TMC8, also named EVER1 and
EVER2, respectively, located within the EV1 locus, were identified
(Ramoz et al., 2002). Eight different mutations of TMC6/EVER1
and 11 mutations of TMC8/EVER2 have been described to date,
in a total of 32 patients from 19 families and 5 ethnicities reviewed
in Burger and Itin (2014) and Imahorn et al. (2017). These
mutations are nonsense, frameshift, or splice-site mutations with
full clinical penetrance for EV in homozygotes and compound
1http://PAVE.niaid.nih.gov
heterozygotes. The effects of these mutations on mRNA and
protein levels have not been investigated in most patients.
Nonsense-mediated RNA decay and undetectable TMC8/EVER2
protein have been reported in two patients with premature stop
codons (Ramoz et al., 2002; Landini et al., 2012). However, splice-
site mutations of TMC8/EVER2 have been identified that have
no effect on mRNA levels, despite the detection of aberrantly
spliced, shorter transcripts (Miyauchi et al., 2016; Imahorn et al.,
2017). Nevertheless, all mutations are assumed to be loss-of-
function. By contrast, the missense polymorphisms found in the
general population are not predicted to be deleterious and are too
common to account for EV. Despite these genetic analyses, more
than 40% of the EV families identified to date have no mutations
of the genes known to be associated with this disease (Zuo et al.,
2006; Arnold et al., 2011; Imahorn et al., 2017) suggesting that
high-throughput sequencing studies are required to identify the
causal genes in these families.
HUMAN GENETICS OF ATYPICAL EV
Inactivating mutations of RHOH (Crequer et al., 2012b), STK4
(encoding the MST1 protein) (Crequer et al., 2012a), CORO1A
(Stray-Pedersen et al., 2014), DCLRE1C (encoding the Artemis
protein) (Tahiat et al., 2017), DOCK8 (Sanal et al., 2012; Liu
et al., 2017), RASGRP1 (Platt et al., 2017), LCK (Li et al., 2016),
and TPP2 (Stepensky et al., 2015) have been reported in patients
with atypical EV. Interestingly, the clinical penetrance of these
genetic disorders for EV lesions is low, as only a few patients
present with manifestations of EV. This is at odds with the
findings for typical EV, which is a fully penetrant Mendelian
trait. A complete loss of function has been reported for all
mutations, except those for Artemis (hypomorphic) and Lck (no
functional investigation). All these patients suffer from a classic
T-cell primary immunodeficiency. Some also display impaired
mitogen- and/or antigen-induced T-cell proliferation. NK cells
counts are normal in all these diseases, except for CORO1A.
Hyper-IgM and hyper-IgE are observed in RASGRP1 and in
CORO1A and DOCK8, respectively. Autoimmunity has been
reported for STK4 and TPP2 deficiencies. T-cell senescence has
been reported for RHOH and TPP2 deficiencies. It remains
unclear whether these observations are the cause or consequence
of severe, disseminated, chronic, life-long beta-HPV and other
recurrent acute and chronic infections in these patients. Few
studies have addressed the specific responses of leukocytes,
but a lack of autologous T-cell response to HPV-infected
keratinocytes has been described (Cooper et al., 1990). Most of
these genes are broadly expressed (including in T cells and other
types of skin-resident cells), with the exception of RHOH and
LCK, which are expressed exclusively in the lymphoid linage
(Table 1). An additional contribution of cells other than T
lymphocytes, including other types of skin-resident cells, to the
pathogenesis of atypical EV cannot, therefore, be ruled out.
Nevertheless, the T-cell defects underlying atypical EV are likely
to be specific, as most inherited and acquired forms of T-cell
deficiency do not cause clinically apparent infections with beta-
HPVs.
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LEUKOCYTE IMMUNITY
Atypical EV is associated with T-cell deficiency. The only
immunological feature common to all known etiologies is CD4+
lymphopenia. More detailed immunological studies have been
performed only in RhoH-deficient patients. These patients had
impaired tissue-homing T-cells marker expression, with a small
decreased in the number of memory skin-homing (CLA+) CD4+
T cells and a large decrease in the number of integrin beta7+
CD4+ T cells. Broad immunological evaluations of patients with
typical EV have proved difficult, due to the rarity of the disease,
and the data available are therefore highly patchy. TMC6/EVER1
and TMC8/EVER2, which are mutated in patients with typical
EV, are widely expressed, including in lymphocytes and the
skin (Lazarczyk et al., 2012). Patients with typical EV have
normal humoral immunity and antibody responses (Jablonska
et al., 1979), their Langerhans cells have normal alloantigen
presentation capacity (Majewski and Jablonska, 1992), and they
have largely normal NK cell activity (Majewski et al., 1986). They
have been reported to display impairments of cellular immunity,
including low T-cell counts, CD4+/CD8+ T-cell ratios, a lack
of responsiveness to T-cell mitogens, anergy to skin antigens
and sensitization to dinitrochlorobenzene (Glinski et al., 1976,
1981; Prawer et al., 1977; Majewski et al., 1986; Majewski and
Jablonska, 1992; Majewski et al., 1997; de Oliveira et al., 2003),
but these defects were inconsistent and further complicated the
assessment of immunological dysfunction in EV patients. All
these observations suggest that a role for TMC6/EVER1 and
TMC8/EVER2 in skin-intrinsic immunity.
KERATINOCYTE IMMUNITY
Keratinocytes contribute to protective immunity in the skin in
at least three ways. First, they form a physical barrier. Second,
they secrete and respond to cytokines, chemokines, and growth
factors, participating in leukocyte-mediated operations (Kupper
and Fuhlbrigge, 2004). Third, keratinocyte-intrinsic mechanisms
are thought to contribute to the control of keratinocyte-
tropic viruses. TMC6/EVER1 and TMC8/EVER2 thus provide
us a unique opportunity to study the role of keratinocytes
in host defense against HPV infection. TMC6/EVER1 and
TMC8/EVER2 belong to a large family of highly conserved
transmembrane channel-like (TMC) proteins that are expressed
in the endoplasmic reticulum, where they act as or modulate
the activity of transmembrane channels (Keresztes et al., 2003;
Kurima et al., 2003). It has been suggested that these two
proteins interact with the zinc transporter ZnT-1, influencing
intracellular Zn2+ concentration, and, thus, the activity of the
transcription factors, such as AP-1, a key activator in the HPV
life cycle and cellular proliferation (Lazarczyk et al., 2008). It has
also been suggested that TMC8/EVER2 influences the cellular
response to TNF-α by promoting apoptosis rather than NF-κB
activation and pro-survival signaling pathways (Gaud et al.,
2013; Vuillier et al., 2014). TMC6/EVER1 and TMC8/EVER2
are thus thought to serve as restriction factors for beta-HPVs
in keratinocytes, through the limitation of viral replication and
gene expression. Studies of TMC6/EVER1 and TMC8/EVER2
have proved technically difficult, partly due to problems raising
robust antibodies against these highly hydrophobic proteins,
which have 10 and 8 transmembrane domains, respectively.
Known molecular functions/mechanism of TMC6/EVER1 and
TMC8/EVER2 are reviewed in Orth (2008) and Lazarczyk
et al. (2009). The cellular and molecular bases of beta-HPV-
driven lesions in TMC6/EVER1 and TMC8/EVER2-deficient
patients with EV remain unknown. The genetic defects prevent
patients from controlling beta-HPV in keratinocytes (Akgul et al.,
2006). The patients are susceptible to skin infections with these
particular types of HPV (Boxman et al., 1999). In addition, some
patients with severe combined immunodeficiency (SCID) caused
by mutations of IL2RG or JAK3 may develop EV. These patients
develop EV only after successful bone marrow transplantation,
indicating that disease development in these patients is related to
a keratinocyte defect (Laffort et al., 2004).
A CLASSIFICATION OF EV INTO TWO
MAJOR TYPES
In the past, EV patients rarely underwent immunological follow-
up, and typical and atypical cases were treated as the same
diagnostic entity. This has led to conflicting reports about the
impairment of immunity in only some patients. Patients with
typical EV probably have a keratinocyte-intrinsic defect allowing
beta-HPVs to persist in the skin, leading to the development
of clinically apparent lesions. Consistent with this notion,
three TMC8/EVER2-deficient EV patients have been reported
to display a largely normal partitioning of circulating T cells,
possibly even with slightly larger than normal skin-homing T-cell
populations (Crequer et al., 2013). These normal numbers of
circulating T cells do not exclude the possibility of an impaired
recognition of and response to HPV-infected keratinocytes
by these cells (Cooper et al., 1990). Once it became clear
that these patients had a selective susceptibility to beta-HPV
infections and TMC6/EVER1 and TMC8/EVER2 deficiencies
had been described as a genetic etiology, EV was identified
as a primary immunodeficiency (Notarangelo et al., 2004;
Orth, 2008; Casanova, 2015). It has been suggested that the
TMC/EVER proteins function as antiviral restriction factors
in keratinocytes, and that they control constitutive intrinsic
immunity (Orth, 2008). Consistent with this hypothesis, patients
with acquired or treatment-induced immunosuppression do
not normally develop EV, despite the commensal nature of
beta-HPVs (Antonsson et al., 2003a,b). This contrasts with
common warts due to alpha-HPVs, which are more common
in immunosuppressed individuals (Wieland et al., 2014). Rare
cases of EV-like syndromes developing in previously unaffected
adults, and known as “acquired EV,” have been described in
patients with suppressed cell-mediated immunity. The clinical
presentations of these patients and proposed treatments have
been reviewed in detail elsewhere (Zampetti et al., 2013; Ovits
et al., 2017). The rarity of atypical EV in patients with broad and
severe genetic T-cell deficiencies and in immunocompromised
individuals suggests that immunosuppression per se is not
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sufficient for the development of this disease. This is the case
for most infectious diseases striking patients with such T-cell
disorders, and it suggests that other host and environmental
factors are involved in pathogenesis.
CONCLUDING REMARKS
In summary, both keratinocytes and T cells probably contribute
to immunity to beta-HPV. Genetic defects affecting one or,
potentially, both cell types lead to the EV-defining clinical
manifestations of beta-HPV infection. All individuals with
severe, recurrent, and persistent flat warts and with a diagnosis
of typical or atypical EV should be tested for genetic etiologies
of typical and atypical EV. The presence and extent of a
systemic T-cell defect determines the spectrum of other clinical
manifestations of an infectious, autoimmune, or allergic nature.
Future studies should provide more conclusive demonstrations of
the keratinocyte-intrinsic nature of EVER-dependent immunity
to beta-HPVs. The identification of new genes associated with
typical and atypical EV will pave the way for analyses of
the molecular and cellular bases of EV, including studies of
the respective contributions of keratinocytes and T cells to
anti-beta-HPV immunity. The highly restricted susceptibility to
beta-HPV observed in patients with EV has important clinical
and biological implications in the fields of HPV, mucocutaneous
immunology, and cell-intrinsic immunity. Elucidation of the
genetic and immunological bases of EV will facilitate studies
of the virulence mechanisms of other HPVs, including the role
of E5 and E8 proteins produced by alpha- and gamma-HPVs,
respectively. These studies will also facilitate the development of
novel approaches for the diagnosis and management of patients
with various conditions due to HPVs.
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